Akebia Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
AKBA$0.53+32.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| (dollars in thousands, except per share amounts) | 2023 | 2022 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $42,925 | $90,466 |
| Inventories | 15,691 | 21,568 |
| Accounts receivable, net | 39,290 | 40,284 |
| Prepaid expenses and other current assets | 20,243 | 32,864 |
| Total current assets | 118,149 | 185,182 |
| Property and equipment, net | 3,629 | 5,214 |
| Operating right-of-use assets | 12,416 | 29,158 |
| Intangible asset, net | 36,042 | 72,084 |
| Goodwill | 59,044 | 59,044 |
| Other long-term assets | 12,423 | 5,372 |
| Total assets | $241,703 | $356,054 |
| Liabilities and stockholders' (deficit) equity | ||
| Current liabilities: | ||
| Accounts payable | $14,635 | $18,021 |
| Accrued expenses and other current liabilities | 67,735 | 75,777 |
| Short-term deferred revenue | — | 3,738 |
| Current portion of long-term debt | 17,500 | 32,000 |
| Total current liabilities | 99,870 | 129,536 |
| Deferred revenue, net of current portion | 43,296 | 43,296 |
| Long-term operating lease liabilities | 8,947 | 28,961 |
| Embedded debt derivative | — | 760 |
| Long-term debt, net | 17,183 | 34,078 |
| Liability related to sale of future royalties | 54,013 | 57,484 |
| Refund liability to customer | 40,093 | 40,992 |
| Other long-term liabilities | 8,885 | 15,717 |
| Total liabilities | 272,287 | 350,824 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' (deficit) equity: | ||
| Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock: $0.00001 par value; 350,000,000 shares authorized at December 31, 2023 and 2022; 194,582,539 and 184,135,714 shares issued and outstanding at December 31, 2023 and 2022, respectively | 2 | 2 |
| Additional paid-in capital | 1,578,358 | 1,562,247 |
| Accumulated other comprehensive income | 6 | 6 |
| Accumulated deficit | (1,608,950) | (1,557,025) |
| Total stockholders' (deficit) equity | (30,584) | 5,230 |
| Total liabilities and stockholders' (deficit) equity | $241,703 | $356,054 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.